You are here

orphan drugs

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

CP Wire

Flag link:

Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer

Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer

CP Wire

Seattle Genetics

clinical trials

HER2-positive metastatic breast cancer

Flag link:

Tetra Discovery Partners Initiates Ph II Trial of Fragile X Syndrome Drug

Tetra Discovery Partners Initiates Ph II Trial of Fragile X Syndrome Drug

CP Wire

Tetra Discovery Partners

Fragile X syndrome

clinical trials

Flag link:

Eagle Receives Orphan Drug Designation for Bendeka

Eagle Receives Orphan Drug Designation for Bendeka

CP Wire

Eagle Pharmaceuticals

Flag link:

Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?

Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?

Forbes

Flag link:

5 Best-Selling Orphan Drugs in the U.S.

5 Best-Selling Orphan Drugs in the U.S.

Motley Fool

Teva Pharmaceutical

Bristol-Myers Squibb

Flag link:

Half of orphan drug sales to come from cancer, Evaluate finds

Half of orphan drug sales to come from cancer, Evaluate finds

Biopharma Dive

Flag link:

Orphan drugs to grow twice as fast as rest of the industry: report

Orphan drugs to grow twice as fast as rest of the industry: report

Medical Marketing and Media

Flag link:

Market Exclusivity is not What Attracts Orphan Drug Investment, Research Finds

Market Exclusivity is not What Attracts Orphan Drug Investment, Research Finds

RAPS.org

market exclusivity

Flag link:

Eloxx Receives Another Orphan-Drug Designation for ELX-02

Eloxx Receives Another Orphan-Drug Designation for ELX-02

CP Wire

Eloxx Pharmaceuticals

Flag link:

EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis

EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis

CP Wire

ATTR amyloidosis

Flag link:

No slowing down: Orphan drug designations skyrocket in 2017

No slowing down: Orphan drug designations skyrocket in 2017

Medical Marketing and Media

Flag link:

Analyzing the orphan drugs market ($127bn)

Analyzing the orphan drugs market ($127bn)

GoinPharma

Flag link:

FDA to Launch New Pilot Program for Orphan Designation Requests

FDA to Launch New Pilot Program for Orphan Designation Requests

RAPS.org

Flag link:

Despite increased spending, orphan drugs still small piece of US medicines market

Despite increased spending, orphan drugs still small piece of US medicines market

Biopharma Dive

Flag link:

FDA is Advancing the Goals of the Orphan Drug Act

FDA is Advancing the Goals of the Orphan Drug Act

FDA Voice

Orphan Drug Act

Flag link:

FDA Determines that Deuterated Compounds are NCEs and Different Orphan Drugs Versus Non-deuterated Versions

FDA Determines that Deuterated Compounds are NCEs and Different Orphan Drugs Versus Non-deuterated Versions

FDA Law Blog

deuterated drugs

Teva Pharmaceutical

Flag link:

FDA Plots Elimination of the Orphan Drug Designation Request Backlog

FDA Plots Elimination of the Orphan Drug Designation Request Backlog

RAPS.org

Flag link:

Orphan drug market set to climb above $200B: Report

Orphan drug market set to climb above $200B: Report

Fierce Pharma

Flag link:

FDA User Fee Package Includes “Technical Corrections” to Address Orphan Drug Clinical Superiority

FDA User Fee Package Includes “Technical Corrections” to Address Orphan Drug Clinical Superiority

FDA Law Blog

Flag link:

Pages